Slow but steady progress is being made in the treatment of lymphoid malignancy, particularly B cell leukaemia, and to a lesser extent non-Hodgkin's lymphoma. One aspect of this field that has attracted particular attention in the last few years has been the use of anti-idiotype antibody in the treatment of B cell tumours. This interest was in part initiated by a report from Miller et al. (1982) of significant regression induced in a patient with advanced B cell lymphoma using a mouse monoclonal anti-idiotype antibody. Although attempts to repeat this finding with other patients have so far met with only limited success the idea of using an anti-idiotype antibody in the treatment of lymphoma remains attractive Stevenson & Glennie, 1985) . If the antibody is ineffective on its own, it may be that it can be endowed with cytotoxicity by being coupled to toxins, drugs or radionuclides. Investigations into therapy with antiidiotype antibody used alone have highlighted a number of problems. For example, not all lymphomas are mono-idiotypic and therefore a cocktail of anti-idiotype antibodies may be necessary (Sklar et al., 1984) ; antigenic modulation provides temporary protection for the tumour cells (Gordon & Stevenson, 1981) and complexing of the anti-idiotype with secreted circulating antibody can provide a further barrier to effective therapy (Stevenson et al., 1980a) . Our investigation of the B cell lymphoma A3 1 indicates that it is probably monoclonal and exhibits only a low level of circulating idiotype which removes two of the obstacles to experimental immunotherapy of mice bearing this tumour.
The characteristics of A3 1 illustrated in the following report, which includes histopathology, immunochemistry, cytogenetics and responses to drugs and radiation, suggest that this tumour may prove valuable in the development of techniques for the effective therapy for B cell lymphoma in man. A31 may also help to increase our understanding of the biology of the normal B lymphocyte.
Materials and methods

Experimental animals
The mice used were inhouse-bred male and female CBA/H. B cell lymphoblastic Iymphoma A31 The tumour arose in 1971 in one of a group of CBA/H female mice injected i.p. 19 months previously with 240 kBq 90Sr. As well as a spindle cell tumour of the spine (probably originating in bone) there was at autopsy an anterior mediastinal tumour mass and an enlarged 'fleshy' spleen. The cells in the thoracic mass (which could have arisen from a tracheobronchial lymph node or the thymus) were malignant lymphocytes, as were the cells infiltrating the spleen. Tumour cells from the mediastinal mass were implanted into CBA/H mice and repeatedly passaged using cells from enlarged spleens (1971-1984; . 100 passages). In 1984 cloning was attempted by i.v. injection of a nominal one cell per mouse into a group of 10 animals. This was repeated on the next passage using the spleen from one of the longest surviving mice. The resultant infiltrated spleens were stored in liquid nitrogen and characterisation commenced.
The data in this paper relate to passages -105-115; and the cells, held in the Radiobiology Unit, are available to other laboratories. Tumour 'takes' can be obtained with a nominal single cell i.v. and 10 cells i.p. or s.c. The s.c. inoculation does not produce a local mass but the draining lymph node becomes larger than the contralateral node.
In this paper we are, for the sake of brevity, calling A3 1 a lymphoma; however, the more cumbersome terms lymphoma/leukaemia, or lymphoblastic lymphoma with terminal leukaemia, would be more accurate as they emphasize that in the terminal phase of the disease there are significant numbers of circulating tumour cells.
Pathology of A31 lymphoma Gross pathological examination was carried out on mice at -20 days and -30 days following the injection of cell numbers varying from 102 to 105; all suspended in PBS and injected i.p., s.c. (dorsum of hind foot) or i.v. Following the autopsy in some mice all the major organs, lymph -nodes and sternum were fixed in either formalin or Bouin's fluid, sectioned and stained with Mayer's haematoxylin and eosin. In other mice the major organs were frozen and cryostat sections cut for indirect staining using our own sheep anti-idiotype, and horse-radish peroxidase-conjugated rabbit antisheep second antibody (Dako Ltd., High Wycombe, Bucks). For cytological examination of A31 imprints were made from the cut surface of the grossly enlarged spleens from terminally affected mice. The imprints were air-dried, methanol fixed and stained with Giemsa, methyl green-pyronin, oil red 0 or Sudan black.
Ultrathin sections of an A3 1 cell pellet were prepared for electron microscopy. The pellets were obtained by teasing apart the enlarged spleens of terminal mice, washing the cells in PBS, centrifuging gently and fixing the pellet in 2.5% glutaraldehyde in 0.1 N sodium cacodylate buffer, postfixing in Millonig's buffered osmium tetroxide (1% OS04) and embedding in Spurr's resin.
Blood for peripheral cell counts was taken on days 7, 14, 21 and 28 following the i.v. injection of 5 mice with 103 A31 cells. A count was made of total lymphocytes, both normal and malignant.
The results from this Pathology section are based on examination of tissues and cells from 90 mice.
Immunogenicity of A31 Twenty male CBA/H mice were inoculated s.c. with A31 cells sterilised by a 2 min exposure to 60Co yrays (total dose 150 Gy). The mice were given 2 inoculations, each of 106 sterilized cells in 0.1ml PBS into opposite flanks separated in time by 2 weeks. Four weeks after the second immunising injection the animals were separated into 2 groups of 10 mice each to be injected s.c. with viable A31 cells. By diluting from 106 cells, suspensions for i.v. injection were prepared of a nominal single cell for one group and 100 cells for the second group. Each of the 2 groups had a companion nonimmunised control group of 10 mice also receiving either 1 or 100 viable cells. The 40 animals were observed until they were killed either because they were moribund, or the study completion date of day 100 after the injection of viable cells was reached.
Immunochemical investigations
Cell suspensions (A31, BCL1, L2C). A31 cells were harvested from the peripheral blood, bone marrow or spleens of CBA/H mice bearing the lymphoma. The details of tumour cell preparation are given separately for each of the procedures.
BCL1 lymphoma cells for immunofluorescence staining were obtained from a line provided by Dr. S. Slavin (Knapp et al., 1979) . It was maintained by passage in the syngeneic host, BALB/c mice. Cells from the spleens of near-terminal animals were disaggregated through a fine gauze in Dulbecco's MEM (Gibco, Paisley) and then isolated by gradient centrifugation on Ficoll-Hypaque followed by washing as described previously (Stevenson et al., 1980b) .
L2C lymphocytic leukaemia cells for immunofluorescence staining (Nadel, 1977) were maintained by continuous passage in strain 2 guinea pigs. Blood was drawn from terminal animals by cardiac puncture into 0.2 vol of 120mM sodium citrate, pH 7.4. The cells were separated and washed as previously described (Gordon & Anderson, 1980 To determine the effect of bacterial lipopolysaccharide (LPS) on A3 1 cells, the lymphomainfiltrated spleens were taken from 3 female CBA/H mice that had been inoculated with 105 tumour cells i.p. 28 days previously, Spleens from agematched normal control mice were used for comparison. The thymidine uptake assay was similar to that described by Roess et al. (1983) . Briefly, LPS from E. coli 0127:B8 (Difco, Detroit, Michigan) was prepared in a doubling dilution series (0.1 ml/well) to cover the range 500upg ml-1 down to 3.9 pg ml -1. Spleen cell suspensions (0.1 ml) were added to the LPS in 96 well culture plates (105 cells/well). For all procedures the culture medium was RPMI 1640 supplemented with pyruvate (1 mmol 1 1), glutamine (2 mmol 1), NaHCO3 (25 mmol 1 1), penicillin (100 IU ml 1), streptomycin (100 pg ml 1), 2-mercaptoethanol (0.05 mmol -1) and heat inactivated foetal bovine serum (5%). The preparations were incubated at 37°C under 5% CO2 in air and after 44h 18.5kBq [6-3H] thymidine ([3H]-TdR Sp.Act. 0.96 TBq mmol-1, Amersham International plc, Amersham, Bucks) was added to each well. Thymidine incorporation was terminated 4 h later by the addition of aminopterin (to a concentration of 0.18mg -1) and the cells harvested onto glass fibre filter papers. The activity retained in the DNA on the filters was measured by liquid scintillation counting.
Cytogenetic preparations
The cells for chromosome analysis were taken from mice killed 9-30 days after i.p. injection of 103 tumour cells (Table I) . Chromosome preparations were made directly from the femoral bone marrow and the spleen, using a modification of Ford's technique (Ford, 1966) . Briefly, the cells were suspended in RPMI 1640 culture medium (Flow Labs., Irvine, Scotland) with 5% foetal bovine serum and subjected to a short exposure of colcemid (Ciba, Horsham, Surrey -0.05 pgml-1 for 10min at 37°C). They were then subjected to hypotonic treatment in 0.5% (w/v) KCI for 15min, followed by fixation in 3 parts methanol to 1 part glacial acetic acid. The cells were resuspended and air dried onto dry slides. The staining was by Brevans mountant (Breckon, 1984) or, after ageing 3-10 days at room temperature, the slides were stained with acetic: saline: Giemsa (ASG)/trypsin and G banded by a modification of the method described by Gallimore & Richardson (1973) . From each sample 5-8 ASG/trypsin karyotypes were prepared from enlarged photographs taken on Kodak Technical Pan 2415 film and a further 10-30 metaphases were analysed directly under the microscope. All grouping and numbering followed the system recommended by the Committee on Standardised Genetic Nomenclature for Mice (C.S.G.N.M, 1972). Chromosome counts (metaphase) to establish clonal distribution are given in Table I .
Short-term (48 h) cultures were established from mice killed 9-30 days after 103 A31 i.p. using cardiac blood and spleen cell suspensions in RPMI 1640 culture medium with 18% heat inactivated foetal bovine serum with 300 jug ml-1 of Lglutamine and stimulated either with concanavalin A (Con A -Pharmacia, Milton Keynes, Bucks; 10 jgml-') for the analysis of predominantly T lymphocytes, or poke-weed mitogen (PWMGibco, Paisley, Scotland; 0.05 ml of reconstituted PWM per 5 ml of culture medium) for the stimulation of predominantly B lymphocytes (Janossy & Greaves, 1971 ). The slide preparation was similar to that used for the direct tissue examination except that the colcemid concentration was 0.01 g mlP-1 for 1-2 h.
Treatment by drugs and X-radiation The response of mice bearing A31 lymphoma was observed following treatment with cyclophosphamide (Farmitalia Carlo Erba Ltd., Barnet, Herts) and vincristine sulphate (Sigma, Poole, Dorset). Both drugs were injected at the maximum tolerated dose. The maximum tolerated dose is defined as that dose which, although not lethal, causes a significant depression in one or more bodily functions and also commonly results in the animal losing weight. The cyclophosphamide was injected on days 15, 21 and 28 following 105 A31 s.c. (i.p. 0.025mgg-1 body wt. twice daily on each day) and vincristine sulphate was given on the same basis except that the dose was 0.5mgg-1 body wt.
and was given only once on each day, and i.p.
The X-irradiation was given at a potentially lethal dose and the animals subsequently rescued by the i.v. injection 24h later of 106 viable bone marrow cells from a normal syngeneic donor. The X-rays were generated from a single source of 250 kV, HVL 1.1mm Cu giving a field uniform to +3%.
The dose rate was 58 m Gy min 1 and the mice were irradiated total body for 2h 40min (9.5Gy). The total body irradiation (TBI) was given to mice 15 The histopathology of early infiltration was examined in mice killed 20 days after the injection of A31 cells. At this time the only gross pathological change was a minimally enlarged spleen. Histopathology (routine paraffin sections and anti-idiotype preparations) of the spleen, Peyer's patches and lymph nodes showed tumour infiltration of the normal B cell domains. The malignant cells occupied approximately 20% of these organs/tissues. The only other organ showing infiltration was the liver where small clusters of A3 1 cells were observed either beneath the endothelium of the centrilobular vein or around the branch of the hepatic artery and adjacent bile duct in the portal areas.
The histopathology at -30 days, as would be expected, showed much more extensive infiltration. By this time the tumour cells had obliterated the splenic architecture leaving only small aggregations of normal lymphocytes around the central arterioles. The lymph nodes and Peyer's patches were also packed with malignant lymphocytes. In some nodes the malignant cells were seen extending into the extra-capsular site (Figure 1) . Scattered in between the malignant lymphocytes were large macrophages giving the tissue a 'starry sky' appearance reminiscent of Burkitt's lymphoma. The liver was heavily infiltrated throughout and moderate infiltration was commonly observed in bone marrow, testis/ovary, lung (peribronchial and perivascular spaces) and adrenal gland. Only (Figure 2) or peripheral blood (data not shown) of tumour-bearing animals. These cells also expressed class II histocompatibility molecules (Ta), but not the T cell marker Thy 1.2 which is present on CBA/H mouse T lymphocytes (Figure 2) .
In addition to surface Ig we have also looked for secretion of IgM by A31 cells during short-term culture in vitro (Figure 3) . IgM is released, probably as a 19S molecule (Stevenson et al., 1980b) , but at levels which are consistent with a low secreting tumour (Stevenson et al., 1980a) . Such an interpretation is supported by the fact that we have been unable to detect a tumour-associated monoclonal band in the serum of A31-bearing mice, even when using sensitive techniques such as isoelectric focusing with immunoprecipitation (data not shown).
Tumour cells from the murine lymphoma BCL1 (Knapp et al., 1979) , and the guinea pig leukaemia L2C (Shevach et al., 1972) , were tested alongside A3 1 cells for the presence of FcR and CR by rosetting with sensitised SRBC. Table III shows that while the BCL1 and L2C tumours were positive for FcR and CR respectively, the A3 1 lymphoma was negative for both. The presence of these receptors on BCL1 and L2C has been described previously (Shevach et al., 1972; Knapp et al., 1979) The effects of LPS on A31 in culture Figure 4 illustrates the striking effect of LPS on [3H]-TdR incorporation into A31 and into normal spleen cells, and Mg ml 1 although this was much reduced at 250 pg ml -1 LPS and at 500 jug ml -1 was not significantly different from zero (0 pg ml-1 LPS). There was obviously a threshold above which LPS was no longer stimulatory to the lymphoma. In making a statistical comparison the data were logarithmically transformed in an attempt to overcome the fact that the variances were (a) greater in groups with high mean cpm than in groups with low mean cpm, and (b) the variances were on average greater for normal spleen cells than for A31 cells. A comparison was then made -=====c2Nc9mk. Table I and Figure 5 . They show that with specific lymphocyte mitogens in the short-term cultures the clone cells carrying the neoplastic chromosome markers (2n=41) were increased in frequency in PWM cultures but not with the mitogen Con A (Table I ). This indicates that the cells which karyotype with the neoplastic chromosome markers are predominantly of B cell origin. In this section on cytogenetics the term clone is used for a population of cells which is assumed to have arisen from one cell and the individual cells have an identical karyotype except for minor deviations. Elsewhere in the paper a clone refers to a population of cells probably originating from one cell, irrespective of any possible differences in karyotype.
The occurrence and percentage of clone cells present altered over time on direct examination. In the bone marrow the percentage of clone cells was maintained at approximately the 10% level until the terminal state (30 days) when it rose to 42%. In the spleen the increase was from 35% at 9 days to a peak of 77% at 20 days with a subsequent decline to 30% at 30 days. In the in vitro cultured cells the percentage of clone cells was zero at 9 days for both spleen and blood indicating that in the spleen and blood detectable infiltration of malignant cells had not occurred at this time. The peak of malignant cells in the cultured spleen was 85% which again was at day 20 post-inoculation, as also was the peak for blood at 80%.
Drug and X-ray treatment of A31 The 2 groups of control non-treatment mice inoculated with 105 A3 1 s.c. died with median survival times of 35 and 36 days (Table II) (Hamblin et al., 1980) or other workers (Rankin et al., 1985) . A number of research groups are examining closely the part that anti-idiotype antibodies may play in the therapy of lymphoma used alone , with attached drugs and toxins (Gilliland et al., 1980; Embleton et al., 1983) , or carrying cellsterilising amounts of radionuclides (Larsen et al., 1983) . In B cell lymphoma/leukaemia a major problem can arise in some patients from large quantities of circulating idiotype which can effectively block the entry of the therapeutic antibody into the tumour infiltrated tissues . It would seem therefore that successful treatment is more likely to be attained in patients with minimal levels of circulating idiotype. The present tumour model, A31 in CBA/H mice, provides a close parallel to aggressive B cell lymphoma in man. As in man the A31 cells infiltrate aggressively the B cell domains of the lymphoreticular system and at a late stage the gonads and, less frequently, the central nervous system (CNS). The infrequency of terminal involvement of the CNS in the mouse might appear to be different from the situation in man where CNS involvement is a common problem. However, in man the CNS is usually only a clinical problem as a site of relapse following treatment. Overt CNS involvement in non-Hodgkin's lymphoma occurs in less than 10% of patients at diagnosis (Levitt et al., 1980) , and in acute lymphoid leukaemia CNS involvement is observed in less than 5% of children at diagnosis, and is rarely symptomatic (Bleyer, 1983) .
We have included in this presentation the results of the response to drugs and X-radiation shown by mice with established B cell lymphoblastic lymphoma. There is clear response to a number of the drugs used in the therapy of this disease in man and also clear response to TBI, which is only rarely used in man for this disease.
The present work has shown that the A3 1 lymphoma is derived from the B cell lineage, expressing surface IgM with a K light chain and the Ia antigen. There was no evidence from immunofluorescence studies of the Thy 1.2. antigen found on T cells, or surface Ig of other isotypes. In particular we found no IgD which has been reported on other murine B cell lymphomas (Knapp et al., 1979) and on the majority of human B cell leukaemias and lymphomas (Fu et al., 1975) . The A31 lymphoma was also negative for surface FcR and CR using the appropriately sensitised SRBC -although their presence on two other animal B cell tumours, BCL1 (FcR) and L2C (CR), was confirmed in the present study (Shevach et al., 1972; Knapp et al., 1979) . The absence of such receptors from the surface of A31 cells compared with BCL1 and L2C, is consistent with a tumour arrested at a different stage of B cell maturation (Rosenberg & Parish, 1977) , or their loss during the process of tumour de-differentiation.
The secretion profile of IgM from A31 cells into the extracellular fluid was assessed during shortterm culture in vitro. Immunoglobulin M was released over a 20 h period, but at levels which were consistent with a low secretor of Ig (Stevenson et al., 1980a) . Previous experience with B cell neoplasms has shown that this material represents small amounts of pentameric IgM released via a secretory pathway, rather than Ig turned over on the cell surface. Any contribution from the cell surface is most likely to occur as vesicle-bound Ig shed from the cells during culture (Stevenson et al., 1980a) . The absence of a detectable monoclonal band in the serum of tumour-bearing animals, even using sensitive techniques such as isoelectric focusing with immunoprecipitation, is also consistent with a low level of secretion.
A31 is potentially an eminently suitable model for immunotherapy investigations using antiidiotype antibodies. Its abundant surface IgM with only minimal IgM secretion should ensure an almost unrestricted access of antibody to the tumour cells. Similar tumours described for the mouse, such as the BC11 of BALB/c, have often secreted significant levels of idiotypic IgM which provides a barrier to any therapeutic antibody (Tutt et al., 1985) . Production of anti-idiotype antibody for the A31 will probably require the isolation of the idiotypic IgM: in the present work idiotypic determinants associated with the whole tumour cell did not prove sufficiently immunogenic to generate a protective immune response. A number of techniques exist to provide this material (Stevenson & Glennie, 1985) , but probably the most straight forward will be the production of a hybridoma between the A3 1 and a non-secreting mouse myeloma such as NS-1, which will secrete the tumour IgM. Armed with the 'rescued' IgM it becomes feasible to hyperimmunise animals for the production of both xenogeneic and syngeneic monoclonal anti-idiotype antibodies .
The cytogenetic studies showed that a characteristic of the dominant clone in the A31 tumour was deletion of an interstitial region of chromosome 2. Hayata et al. (1983) have reported deletion and loss of a segment of chromosome 2 in 44 of 52 cases of X-ray induced murine myeloid leukaemia. This change was seen irrespective of differences in mouse strain, sex and stage of tumour differentiation. This chromosome abnormality however was not observed in 30 cases of murine lymphoid leukaemia (Hayata, unpublished data) nor in 9 cases of nonmyeloid leukaemia examined in this laboratory. As far as we are aware this is the first observation of a chromosome 2 rearrangement in a non-myeloid leukaemia. The partial trisomy of chromosome 2 in A3 1 is a new observation as is the loss of chromosome 6, unless a part is translocated to either marker 1 or 2. Translocation of part of chromosome 11 is an uncommon event as is trisomy for 17. Variation in the presence or absence of the Y chromosome together with duplication is a common event in human and mouse myeloid leukaemia.
In summary, we are reporting the characteristics of a new murine B cell lymphoma which show that it is similar in many ways to aggressive B cell lymphoma in man. This would make it a useful model for the therapy of this disease and in addition it may be of value in expanding our knowledge of the biology of both normal and malignant B lymphocytes of mice and men.
